On June 4, 2025, Cullinan Therapeutics, Inc. signed a License Agreement with Chongqing Genrix Biopharmaceutical Co., granting an exclusive global license to develop and commercialize a drug, with an upfront fee of $20 million and potential payments totaling $692 million.